105 related articles for article (PubMed ID: 2904696)
1. Vitamin E in the treatment of tardive dyskinesia: the possible involvement of free radical mechanisms.
Lohr JB; Cadet JL; Lohr MA; Larson L; Wasli E; Wade L; Hylton R; Vidoni C; Jeste DV; Wyatt RJ
Schizophr Bull; 1988; 14(2):291-6. PubMed ID: 2904696
[TBL] [Abstract][Full Text] [Related]
2. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia.
Lohr JB; Caligiuri MP
J Clin Psychiatry; 1996 Apr; 57(4):167-73. PubMed ID: 8601552
[TBL] [Abstract][Full Text] [Related]
3. Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group.
Adler LA; Rotrosen J; Edson R; Lavori P; Lohr J; Hitzemann R; Raisch D; Caligiuri M; Tracy K
Arch Gen Psychiatry; 1999 Sep; 56(9):836-41. PubMed ID: 12892048
[TBL] [Abstract][Full Text] [Related]
4. No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients.
Silver H; Geraisy N; Schwartz M
J Clin Psychiatry; 1995 Apr; 56(4):167-70. PubMed ID: 7713856
[TBL] [Abstract][Full Text] [Related]
5. The Nithsdale Schizophrenia Surveys. XIV: Plasma lipid peroxide and serum vitamin E levels in patients with and without tardive dyskinesia, and in normal subjects.
McCreadie RG; MacDonald E; Wiles D; Campbell G; Paterson JR
Br J Psychiatry; 1995 Nov; 167(5):610-7. PubMed ID: 8564316
[TBL] [Abstract][Full Text] [Related]
6. The effect of vitamin E treatment on tardive dyskinesia and blood superoxide dismutase: a double-blind placebo-controlled trial.
Zhang XY; Zhou DF; Cao LY; Xu CQ; Chen DC; Wu GY
J Clin Psychopharmacol; 2004 Feb; 24(1):83-6. PubMed ID: 14709952
[TBL] [Abstract][Full Text] [Related]
7. White matter abnormalities in schizophrenia patients with tardive dyskinesia: a diffusion tensor image study.
Bai YM; Chou KH; Lin CP; Chen IY; Li CT; Yang KC; Chou YH; Su TP
Schizophr Res; 2009 Apr; 109(1-3):167-81. PubMed ID: 19261444
[TBL] [Abstract][Full Text] [Related]
8. Treatment of tardive dyskinesia with vitamin E.
Egan MF; Hyde TM; Albers GW; Elkashef A; Alexander RC; Reeve A; Blum A; Saenz RE; Wyatt RJ
Am J Psychiatry; 1992 Jun; 149(6):773-7. PubMed ID: 1350428
[TBL] [Abstract][Full Text] [Related]
9. Tardive dyskinesia and impaired glucose tolerance.
Chong SA; Mythily ; Lum A; Huak CY; Kane J
Hum Psychopharmacol; 2002 Aug; 17(6):305-7. PubMed ID: 12404676
[TBL] [Abstract][Full Text] [Related]
10. Vitamin B6 in treatment of tardive dyskinesia: a preliminary case series study.
Lerner V; Kaptsan A; Miodownik C; Kotler M
Clin Neuropharmacol; 1999; 22(4):241-3. PubMed ID: 10442256
[TBL] [Abstract][Full Text] [Related]
11. Long-term treatment effects of vitamin E for tardive dyskinesia.
Adler LA; Edson R; Lavori P; Peselow E; Duncan E; Rosenthal M; Rotrosen J
Biol Psychiatry; 1998 Jun; 43(12):868-72. PubMed ID: 9627740
[TBL] [Abstract][Full Text] [Related]
12. Tardive dyskinesia outcomes: clinical and pharmacologic correlates of remission and persistence.
Cavallaro R; Regazzetti MG; Mundo E; Brancato V; Smeraldi E
Neuropsychopharmacology; 1993 May; 8(3):233-9. PubMed ID: 8099483
[TBL] [Abstract][Full Text] [Related]
13. Oxidative mechanisms and tardive dyskinesia.
Lohr JB; Kuczenski R; Niculescu AB
CNS Drugs; 2003; 17(1):47-62. PubMed ID: 12467492
[TBL] [Abstract][Full Text] [Related]
14. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
Soares-Weiser K; Rathbone J
Cochrane Database Syst Rev; 2006 Jan; (1):CD000459. PubMed ID: 16437425
[TBL] [Abstract][Full Text] [Related]
15. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
Bai YM; Yu SC; Lin CC
J Clin Psychiatry; 2003 Nov; 64(11):1342-8. PubMed ID: 14658949
[TBL] [Abstract][Full Text] [Related]
16. [Tardive dyskinesia induced by classical antipsychotic drugs: a Tunisian sample of schizophrenics].
Sejil I; Oumaya A; Bouguerra C; Mehdi F; Bellaaj R; Gallali S
Encephale; 2013 May; 39 Suppl 1():S36-41. PubMed ID: 23219594
[TBL] [Abstract][Full Text] [Related]
17. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
McGrath JJ; Soares KV
Cochrane Database Syst Rev; 2000; (2):CD000459. PubMed ID: 10796546
[TBL] [Abstract][Full Text] [Related]
18. The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders.
de Jesus Mari J; Lima MS; Costa AN; Alexandrino N; Rodrigues-Filho S; de Oliveira IR; Tollefson GD
Eur Arch Psychiatry Clin Neurosci; 2004 Dec; 254(6):356-61. PubMed ID: 15538607
[TBL] [Abstract][Full Text] [Related]
19. Ginkgo biloba leaf extract and alpha-tocopherol attenuate haloperidol-induced orofacial dyskinesia in rats: Possible implication of antiapoptotic mechanisms by preventing Bcl-2 decrease and Bax elevation.
An HM; Tan YL; Shi J; Wang Z; Lv MH; Soares JC; Zhou D; Yang F; Zhang XY
Phytomedicine; 2016 Dec; 23(13):1653-1660. PubMed ID: 27823630
[TBL] [Abstract][Full Text] [Related]
20. Awareness of tardive dyskinesia in Asian patients with schizophrenia.
Chong SA; Remington G; Mahendran R; Chua HC
J Clin Psychopharmacol; 2001 Apr; 21(2):235-7. PubMed ID: 11270922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
